Abstract PO-007: Plasma-based detection of pancreatic cancer: A multiomics approach
Published: Nov 15, 2021
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with an overall five-year survival rate of 11%. Potential curative resection is possible if the tumor is detected at an early stage, with a five-year survival rate of 42%. The only current FDA-cleared biomarker for PDAC is the carbohydrate antigen 19-9 (CA19-9), which is intended for monitoring response to therapy but not for early detection. CA19-9 blood tests have varying...
Paper Details
Title
Abstract PO-007: Plasma-based detection of pancreatic cancer: A multiomics approach
Published Date
Nov 15, 2021
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History